-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Vor Biopharma, Lowers Price Target to $40

Benzinga·12/19/2025 16:25:02
Listen to the news
JP Morgan analyst Anupam Rama maintains Vor Biopharma (NASDAQ:VOR) with a Overweight and lowers the price target from $43 to $40.